Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAA-sT
- Development stage
- Unknown
- Lead developer
- Union Hospital of Huazhong University of Science and Technology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TAA-sT is an experimental adoptive T-cell therapy developed by researchers at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. The therapy involves the ex vivo expansion of T cells that are specifically primed to recognize a panel of five tumor-associated antigens (TAAs): Wilms tumor protein (WT1), Survivin (BIRC5), PRAME, MAGE-A3, and NY-ESO-1. These antigens are frequently overexpressed in non-small cell lung cancer (NSCLC) but have limited expression in normal tissues. By targeting multiple antigens simultaneously, TAA-sT aims to provide a robust and polyvalent immune response, reducing the likelihood of tumor escape through antigen loss and addressing the inherent heterogeneity of advanced lung tumors. The product is administered via intravenous infusion to patients with advanced or metastatic NSCLC.
- Other names
- Tumor-associated antigen-specific T cellsTAA-specific T cells
02
Targets
WT1 (Wilms tumor protein)PRAME (Preferentially expressed antigen in melanoma)NY-ESO-1 (New york esophageal squamous cell carcinoma 1)BIRC5 (Survivin)MAGEA3 (Melanoma-associated antigen 3)
Beyond the preview
Go deeper on TAA-sT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAA-sT.